[1] Martin E F. Liver transplantation for primary biliary cholangitis [J]. Clin Liver Dis, 2022, 26(4): 765-781.
[2] Webb G J, Rana A, Hodson J, et al. Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists [J]. Clin Gastroenterol Hepatol, 2018, 16(2): 278-287.e7.
[3] Zeng N, Duan W, Chen S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis [J]. Hepatol Int, 2019, 13(6): 788-799.
[4] Singal A K, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease [J]. Transplantation, 2013, 95(5): 755-760.
[5] Montaon-Loza A J, Hansen B E, Corpechot C, et al. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival [J]. Gastroenterology, 2019, 156(1): 96-107.e1.
[6] 尤红, 段维佳, 李淑香, 等. 原发性胆汁性胆管炎的诊断和治疗指南(2021) [J]. 临床肝胆病杂志, 2022, 38(01): 35-41.
[7] Lindor K D, Bowlus C L, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases [J]. Hepatology, 2019, 69(1): 394-419.
[8] Singal A K, Fang X, Kaif M, et al. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation [J]. Transpl Int, 2017, 30(5): 454-462.
[9] Zhou K, Dodge J L, Xu E, et al. Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation [J]. Clin Transplant, 2022, 36(2): e14527.
[10] Goet J C, Murillo Perez C F, Harms M H, et al. A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis [J]. Am J Gastroenterol, 2021, 116(7): 1514-1522.
[11] Gross C R, Malinchoc M, Kim W R, et al. Quality of life before and after liver transplantation for cholestatic liver disease [J]. Hepatology, 1999, 29(2): 356-364.
[12] Corpechot C, Chazouillères O, Belnou P, et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis [J]. J Hepatol, 2020, 73(3): 559-565.
[13] Silveira M G, Talwalkar J A, Lindor K D, et al. Recurrent primary biliary cirrhosis after liver transplantation [J]. Am J Transplant, 2010, 10(4): 720-726.
[14] Montano-Loza A J, Lytvyak E, Hirschfield G, et al. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation [J]. J Hepatol, 2024, 81(4): 679-689.
[15] Montano-Loza A J, Corpechot C, Burra P, et al. Recurrence of autoimmune liver diseases after liver transplantation: review and expert opinion statement [J]. Liver Transpl, 2024.
[16] Egawa H, Sakisaka S, Teramukai S, et al. Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: a Japanese multicenter study [J]. Am J Transplant, 2016, 16(4): 1248-1257.
[17] Kogiso T, Egawa H, Teramukai S, et al. Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: a Japanese multicenter retrospective study [J]. Hepatol Commun, 2017, 1(5): 394-405.
[18] Liermann Garcia R F, Evangelista Garcia C, McMaster P,et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center [J]. Hepatology, 2001, 33(1): 22-27.
[19] Charatcharoenwitthaya P, Pimentel S, Talwalkar J A, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation [J]. Liver Transpl, 2007, 13(9): 1236-1245.
[20] Balan V, Ruppert K, Demetris A J, et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database [J]. Hepatology, 2008, 48(3): 878-888.
[21] Sanchez E Q, Levy M F, Goldstein R M, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation [J]. Transplantation, 2003, 76(11): 1583-1588.
[22] Neuberger J, Gunson B, Hubscher S, et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation [J]. Liver Transpl, 2004, 10(4): 488-491.
[23] Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients [J]. Clin Transplant, 2006, 20(2): 211-220.
[24] Montano-Loza A J, Wasilenko S, Bintner J, et al. Cyclosporine a protects against primary biliary cirrhosis recurrence after liver transplantation [J]. Am J Transplant, 2010, 10(4): 852-858.
[25] Li X, Peng J, Ouyang R, et al. Risk factors for recurrent primary biliary cirrhosis after liver transplantation: a systematic review and meta-analysis [J]. Dig Liver Dis, 2021, 53(3): 309-317.
[26] Dmitrewski J, Hubscher S G, Mayer A D, et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression [J]. J Hepatol, 1996, 24(3): 253-257.
[27] Carbone M, Mells G F, Alexander G J, et al. Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation [J]. Am J Transplant, 2013, 13(4): 1110-1111.
[28] Tanaka A, Leung P S C, Gershwin M E. Pathogen infections and primary biliary cholangitis [J]. Clin Exp Immunol, 2019, 195(1): 25-34.
[29] Montano-Loza A J, Bhanji R A, Wasilenko S, et al. Systematic review: recurrent autoimmune liver diseases after liver transplantation [J]. Aliment Pharmacol Ther, 2017, 45(4): 485-500.
[30] van Hooff M C, de Veer R C, Karam V, et al. Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis - an ELTR study [J]. JHEP Rep, 2024, 6(8): 101100.
[31] Rowe I A, Webb K, Gunson B K, et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience [J]. Transpl Int, 2008, 21(5): 459-465.
[32] You H, Ma X, Efe C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis [J]. Hepatol Int, 2022, 16(1): 1-23.
[33] Bosch A, Dumorier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence [J]. J Hepatol, 2015, 63(6): 1449-1458.
[34] Pedersen M R, Greenan G, Arora S, et al. Ursodeoxycholic acid decreases incidence of primary biliary cholangitis and biliary complications after liver transplantation: a meta-analysis [J]. Liver Transpl, 2021, 27(6): 866-875. |
